Purespring Therapeutics has raised $105m in a Series B funding round which will help progress its lead candidate PS-002 to ...

London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of ...

Biotechnology company Purespring Therapeutics has raised about $105 million to fund its development of gene therapies for ...

Purespring Therapeutics, a UK-based gene therapy company focused on kidney disease, has raised £80 million ($105 million) in ...

Purespring Therapeutics Ltd. has raised £80 million (US$104.6 million) in a series B, putting it on course to be the first to ...

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseasesOversubscribed financing led ...

The London-based firm said it will use the funds to advance its gene therapy pipeline, including its lead program in IgA nephropathy.

A University of Bristol spinout company focused on transforming the way kidney diseases are treated has announced an £80m ...

Purespring raises £80 million in a Series B financing, with Syncona committing £19.9 million[1] as part of a leading syndicate of life science investorsProceeds will be used to advance Purespring’s ...

A Bluebird Bio gene therapy has helped children with a devastating neurological disorder, but seven have developed blood ...

Since the FDA cleared Sarepta Thereapeutics' gene therapy for nearly all people with Duchenne, its stock price has tanked.

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases ...